board of directors
- management team
- board of directors
- founders
- investors
Robert Connelly Chief Executive Officer
David A. Edwards, Ph.D. Professor of Biomedical Engineering, Harvard University
Steven Gillis, Ph.D. Managing Director, ARCH Venture Partners
David Maki General Partner, Altitude Life Sciences Ventures
Terry McGuire Co-Founder and Managing Partner, Polaris Venture Partners
Scott Rocklage, Ph.D. Managing Partner, 5AM Ventures
Dr. Rocklage joined 5AM Ventures in 2003 as a Venture Partner and became a Managing Partner in 2004. Dr. Rocklage has over 20 years of healthcare management experience with strategic leadership responsibilities that have resulted in the successful approval of three U.S. New Drug Applications by the FDA (Omniscan™, Teslascan® and Cubicin®), and entered six drug candidates into clinical trials. Dr. Rocklage has served as Chairman & CEO of Cubist Pharmaceuticals, President & CEO of Nycomed Salutar, President, CEO, & Chairman of Nycomed Interventional, and has held various R&D positions at Salutar and Catalytica. Dr. Rocklage currently serves as Board Chairman of Achaogen, Relypsa, and Semprus, as well as on the Boards of WaveRx and Variation, and the Board of Associates at the Whitehead Institute. Dr. Rocklage received his B.S. in Chemistry from the University of California, Berkeley, and his Ph.D. in Chemistry from the Massachusetts Institute of Technology.
Lauren Silverman, Ph.D. Managing Director, Novartis Option Fund